EC approves Bristol-Myers’ Opdivo (nivolumab) for SCCHN in adults
Bristol-Myers announced the EEC has approved Opdivo (nivolumab) as monotherapy for treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy. Opdivo is the only I-O treatment that demonstrated in a Phase 3 trial a significant improvement in OS. April 28, 2017